SYNTARA LIMITED — Capital/Financing Update 2007

Nov 15, 2007

1Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity

Pharmaxis Ltd

ABN

75 082 811 630

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Pharmaxis Ltd ordinary shares

• 2 Number of +securities issued or to be issued (if known) or maximum number which may be issued 2,999,074
• 3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Issue of fully paid ordinary shares under the Share Purchase Plan announced to the market on 11th October 2007 and closed on 9th November 2007.

+ See chapter 19 for defined terms.

4	Do the +securities rank equally in allrespects from the date of allotmentwith an existing +class of quoted+securities?If the additional securities do not	Yes.
	rank equally, please state:•the date from which they do•theextenttowhichtheyparticipate for the next dividend,(inthecaseofatrust,distribution) or interest payment•the extent to which they do notrankequally,otherthaninrelation to the next dividend,distribution or interest payment
5	Issue price or consideration	$3.90
6	Purpose of the issue(If issued as consideration for theacquisition of assets, clearly identifythose assets)	Together with the recent share placement, tostrengthen the balance sheet of the Company asit enters a period of significant investment andposition Pharmaxis to continue with its growthstrategy.Upcominginvestmentsincludeclinical trials and marketing of Bronchitol andAridol and the fit-out of a new purpose-builtfacilitytohousePharmaxis'research,manufacturing, clinical, sales and marketing andadministrative activities.
7	Dates of entering +securities intouncertificated holdings or despatchof certificates	16th November 2007
8	+classNumberandofall	Number194,424,554	+ClassOrdinaryfullypaid
	+securitiesquotedonASX(including the securities in clause2 if applicable)		shares

+ See chapter 19 for defined terms.

		Number	+Class
9	+classNumberandofall	1,220,000	Optionsexpiringon
	+securities not quoted on ASX		various dates with an
	(including the securities in clause		exercisepriceof
	2 if applicable)		$0.125(ASXCode
			PXSAM)
		4,186,000	Optionsexpiringon
			various dates with an
			exercisepriceof
			$0.3125 (ASX Code
			PXSAO)
		500,000	Optionsexpiring30
			November 2013 with
			an exercise price of
			$0.376(ASXCode
			PXSAQ)
		22,500	Optionsexpiring24
			March 2014 with an
			exercisepriceof
			$0.508(ASXCode
			PXSAS)
		15,000	Optionsexpiring3
			June2014withan
			exercisepriceof
			$0.426(ASXCode
			PXSAU)
		240,000	Optionsexpiring1
			February 2015 with an
			exercisepriceof
			$0.8340 (ASX Code
			PXSAY)
		320,000	Optionsexpiring11
			May2015withan
			exercisepriceof
			$1.147(ASXCode
			PXSAW)
		786,250	Optionsexpiring4
			August 2015 with an
			exercise price of $1.79
			(ASX Code PXSAZ)
		70,000	Optionsexpiring17
			October 2015 with an
			exercisepriceof
			$2.772(ASXCode
			PXSAA)

+ See chapter 19 for defined terms.

260,000	Optionsexpiring12
	February 2016 with an
	exercisepriceof
	$2.194(ASXCode
	PXSAB)
96,500	Optionsexpiring31
	May2016withan
	exercisepriceof
	$2.034(ASXCode
	PXSAC)
893,707	Optionsexpiring14
	August 2016 with an
	exercisepriceof
	$1.917(ASXCode
	PXSAD)
47,500	Optionsexpiring19
	September 2016 with
	an exercise price of
	$1.8918 (ASX Code
	PXSAE)
45,000	Optionsexpiring13
	December 2016 with
	an exercise price of
	$3.0710 (ASX Code
	PXSAF)
200,000	Optionsexpiring15
	March 2016 with an
	exercisepriceof
	$2.0680 (ASX Code
	PXSAG)
237,500	Optionsexpiring17
	June2017withan
	exercisepriceof
	$3.3155 (ASX Code
	PXSAH)
1,633,000	Optionsexpiring9
	August 2017 with an
	exercisepriceof
	$3.33890 (ASX Code
	PXSAL)
150,000	Optionsexpiring9
	August 2017 with an
	exercisepriceof
	$3.33890 (ASX Code
	PXSAI)
200,000	Optionsexpiring14
	November 2016 with
	an exercise price of
	$3.32258 (ASX Code
	PXSAK)

+ See chapter 19 for defined terms.

		527,000	Optionsexpiring5November 2017 withan exercise price of$4.2900 (ASX CodePXSAT)
10	Dividend policy (in the case of atrust, distribution policy) on theincreased capital (interests)	Nochangefromprospectus dated 26 September 2003	policydisclosedinthe

Part 2 - Bonus issue or pro rata issue

11	Issecurityholderapprovalrequired?
12	Is the issue renounceable or nonrenounceable?
13	Ratio in which the +securities willbe offered
14	+Class of +securities to which theoffer relates
15	+Recorddatetodetermineentitlements
16	Will holdings on different registers(or subregisters) be aggregated forcalculating entitlements?
17	Policy for deciding entitlements inrelation to fractions
18	Names of countries in which theentity has +security holders whowillnotbesentnewissuedocumentsNote: Security holders must be told how theirentitlements are to be dealt with.Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations

+ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters
21	Amount of any underwriting fee or
	commission
22	Names of any brokers to the issue
23	Fee or commission payable to thebroker to the issue
24	Amountofanyhandlingfeepayabletobrokerswholodge
	acceptances or renunciations on
	behalf of +security holders
25	Iftheissueiscontingenton
	+security holders' approval, the
	date of the meeting
26	Date entitlement and acceptance
	form and prospectus or Product
	Disclosure Statement will be sent to
	persons entitled
27	If the entity has issued options, and
	the terms entitle option holders to
	participate on exercise, the date onwhich notices will be sent to option
	holders
28	Date rights trading will begin (ifapplicable)
29	Date rights trading will end (if
	applicable)
30	How do +security holders sell theirentitlementsinfullthrougha
	broker?
31	How do +security holders sell partof their entitlements through a
	broker and accept for the balance?

32 How do +security holders dispose of their entitlements (except by sale through a broker)?

33 +Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities (tick one)
• (a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

				Tick to indicate you are providing the information or
documents

I٦-	٦-

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

37 A copy of any trust deed for the additional +securities

+ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

• 38 Number of securities for which +quotation is sought
• 39 Class of +securities for which quotation is sought
• 40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

• the date from which they do
• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
• 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

Number	+Class

	Number	+Class
Number and +class of all +securities42quotedonASX(includingthesecurities in clause 38)

+ See chapter 19 for defined terms.

Quotation agreement

• 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
• 2 We warrant the following to ASX.
  • The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  • There is no reason why those +securities should not be granted +quotation.
  • An offer of the + securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
• We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the +securities to be quoted, it has been provided at the time that we request that the +securities be quoted.
• If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

+ See chapter 19 for defined terms.

• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
• 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

(Company secretary)

Sign here: ...................................................... Date: 16th November 2007

Print name: ......David McGarvey............

== == == == ==

+ See chapter 19 for defined terms.